195 followers
@ehj_ed @ESC_Journals @escardio Table 3 seems to provide a comprehensive list of studies of ruxolitinib and thromboembolic events. Not included were JANUS 1 and 2 phase 3 trials showing elevated rates of pulmonary embolism. https://t.co/BAn5obgRft